Can Mesenchymal Stem Cells Treat Scars? A Regenerative Medicine Review
From keloids to burn scars, traditional treatments often fall short. New research reveals how MSCs may transform scar management through anti-fibrotic and regenerative mechanisms.
Understanding Scar Formation
Scars form as the body's natural response to wound healing. When the dermis (the deep, thick layer of skin) is damaged, the body produces collagen fibers to repair the wound. However, this emergency repair collagen is structurally different from the original tissue — it's laid down in parallel bundles rather than the basket-weave pattern of normal skin, resulting in a scar that differs in texture, flexibility, and appearance.
In some individuals, the scarring response overshoots. Hypertrophic scars develop when the body produces too much collagen within the wound boundaries, creating a raised, firm, red scar. Keloids go further, growing beyond the original wound margins and continuing to expand over time. These pathological scars affect an estimated 100 million people worldwide annually and can cause significant physical discomfort (itching, pain, restricted movement) and psychological distress.
Traditional scar treatments — including silicone sheets, corticosteroid injections, laser therapy, surgical revision, and radiation — can improve scar appearance but rarely restore skin to its pre-injury state. Recurrence rates for keloids after surgical excision alone can reach 50-80%, highlighting the need for treatments that address the underlying fibrotic biology rather than just the visible scar.
How MSCs Work on Scars
Anti-Fibrotic Signaling
MSCs secrete factors that directly inhibit excessive collagen production by fibroblasts. They downregulate TGF-β1 (the main driver of fibrosis) while upregulating TGF-β3 (associated with scarless healing seen in fetal wounds). This rebalancing shifts the wound from a fibrotic to a regenerative healing pathway.
Collagen Remodeling
MSCs release matrix metalloproteinases (MMPs) that break down excess, disorganized scar collagen. Simultaneously, they promote the deposition of properly organized collagen in a normal basket-weave pattern. This dual action — degrading pathological collagen while promoting normal collagen — gradually transforms scar tissue toward normal skin architecture.
Skin Regeneration
MSC-derived growth factors stimulate the regeneration of skin appendages (hair follicles, sweat glands) that are typically absent in scar tissue. They also promote the formation of elastic fibers, restoring the skin's flexibility and reducing the stiffness characteristic of mature scars.
Immune Modulation
MSCs modulate the local immune response within scar tissue, reducing the chronic inflammation that drives keloid growth and scar expansion. By shifting macrophage polarization from pro-fibrotic (M2a) to anti-fibrotic (M2c) phenotypes, MSCs help create an environment that favors tissue remodeling over continued fibrosis.
Clinical Evidence
A comprehensive 2025 review published in Biomaterials Research analyzed data from 11 clinical studies investigating MSC-based scar treatments. The review found consistent evidence that MSC therapy improved scar appearance, reduced scar thickness, and improved patient-reported outcomes across multiple scar types.
In keloid studies, intralesional injection of MSC-conditioned media resulted in significant reduction in keloid volume (average 40-55% reduction) with lower recurrence rates compared to corticosteroid injection alone. For burn scars, MSC treatment improved both the Vancouver Scar Scale scores and range of motion in affected joints, indicating both aesthetic and functional improvement.
A 2024 randomized controlled trial investigating MSC-derived exosomes combined with microneedling for acne scarring reported significant improvements in scar depth and skin texture compared to microneedling alone, with patient satisfaction rates exceeding 80% in the treatment group.
While results are promising, most studies have relatively small sample sizes and short follow-up periods. Larger, multicenter trials with longer observation are needed to establish optimal protocols and long-term efficacy. Results vary between individuals, and stem cell scar treatment should be discussed with a qualified dermatologist or plastic surgeon.
Scar Types & MSC Treatment Approaches
Keloid Scars
MSC injections combined with traditional treatments show the strongest evidence for keloids. MSCs can reduce keloid volume, prevent recurrence after surgical excision, and alleviate symptoms like itching and pain. Combination protocols (surgery + MSC injection) show recurrence rates as low as 10-15% compared to 50-80% with surgery alone.
Hypertrophic Scars
MSC therapy can reduce scar height, redness, and stiffness. The anti-fibrotic properties of MSCs help remodel excessive collagen deposits, while growth factors improve skin flexibility. Improvements in both appearance and function have been documented in clinical trials.
Burn Scars
For extensive burn scarring, MSC treatment aims to improve skin flexibility, reduce contracture, and restore skin appendage function. Studies show improvement in range of motion, reduced pain, and better skin quality after MSC treatment. Both injection and topical scaffold-based delivery have been used.
Acne Scars
MSC-derived growth factors and exosomes, often combined with microneedling, stimulate collagen production in atrophic (depressed) acne scars. This approach fills in pitted scars from below and improves overall skin texture. Multiple sessions are typically required for optimal results.
Surgical Scars
Prophylactic MSC application during wound closure may prevent excessive scarring after surgery. Early studies suggest that MSC-loaded wound dressings applied immediately post-surgery result in thinner, softer, and less visible scars compared to standard closure techniques.
Frequently Asked Questions
Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Results vary between individuals. Always consult with qualified healthcare professionals before making treatment decisions. StemCell Longevita operates as an international patient coordination platform.
التنسيق الدولي للمرضى
تعمل StemCell Longevita كمنصة تنسيق دولية للمرضى. نربط المرضى بالمؤسسات الطبية المرخصة التي تقدم تطبيقات الطب التجديدي بعد تقييم الطبيب وضمن الأطر التنظيمية المعمول بها. جميع القرارات والإجراءات الطبية يتم اتخاذها حصرياً من قبل متخصصين صحيين مرخصين. StemCell Longevita لا تقدم علاجاً طبياً مباشراً.
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as medical advice. Stem cell therapy is an evolving field, and outcomes may vary by individual. The treatments described on this site have not been fully evaluated or approved by the FDA or equivalent regulatory bodies in all jurisdictions.
The FDA has not approved stem cell applications for most conditions listed on this website. Results mentioned are based on clinical observations, published research, and patient-reported outcomes. Individual results may vary and no specific outcomes are assured for any individual patient.
إدراج المنشورات العلمية على هذا الموقع لا يعني الموافقة التنظيمية أو نتائج سريرية مضمونة. قد تُعتبر بعض التطبيقات تجريبية حسب الاستطباب والاختصاص القضائي.
Always consult with a qualified healthcare professional before making any medical decisions. Do not disregard professional medical advice or delay seeking treatment based on information found on this website.